IL6 and Alzheimer disease: As shown in Fig. 5a, TgDNMT1-induced levels of TNFα, IL-1β and IL-6 in the plasma of ApoE−/− mice on an AD were largely attenuated by rosiglitazone treatment (Fig. 5a), while TgDNMT1-suppressed plasma IL-10 levels were, to a great extent, rescued by rosiglitazone (Fig. 5a).